Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Ryan Layer, The Conversation | May 27, 2022 | 5 min read
Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.
A neurologist by training, Stefánsson founded Iceland-based deCODE Genetics to explore what the human genome can tell us about disease and our species’ evolution.
A reference sequence for this emerging model organism will facilitate research on type 2 diabetes and the health effects of circadian rhythm disruption.
So far, six animal species are known to carry transmissible, “parasitic” forms of cancer, but researchers are still mystified as to how cancer can become infectious.